Advertisement

Prolactin-Secreting Tumors

  • C. R. Kannan
Part of the Clinical Surveys in Endocrinology book series (CSED, volume 1)

Abstract

Prolactin-secreting tumors are the most frequently encountered pituitary disorders in clinical practice. The realization that nearly 40% of so-called nonse- cretory and functionless pituitary tumors actually contain prolactin was an exciting one.1 This realization in conjunction with the development of a sensitive immunoassay for prolactin, the emergence of high-quality computed tomography (CT), and the discovery of dopamine agonist drugs has resulted
Table 75

Spectrum of Hyperprolactinemia

Condition

Serum prolactin (ng/ml)

Comment

Idiopathic hyperprolactinemia

↑ mild (<100)↑ ↑(100–300)

CT negative; no lesions in the pituitary or hypothalamus; benign, often self-limited course; does not progress into tumors

Microprolactinomas

↑ ↑ (100–300)

Tumors <1 cm by CT No impairment in pituitary function; does not usually progress to microadenomas; negligible chances of enlargement during pregnancy

Macroprolactinomas

↑ ↑ ↑ >300

Tumors > cm by CT May impair pituitary function and often causes chiasmal compression

Invasive prolactinomas

↑ ↑ ↑ (500–2000)

Tumor >1 cm wit extension Often impairs pituitary function and often causes chiasmal compression

Pseudoprolactinoma

Variably ↑

Large nonsecretory tumor (negative staining for prolactin), with pressure on hypothalamicpituitary stalk. Interruption of dopamine transport elevates PRL

in a remarkably rapid growth in the understanding of prolactin-related disorders.

Keywords

Pituitary Adenoma Pituitary Tumor Secondary Amenorrhea Bromocriptine Treatment Bromocriptine Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Peake GT, McKeel DW, Jarett L, et al: Ultrastructural, histologic and hormonal characterisation of a prolactin rich human pituitary tumour. J Clin Endocrinol Metab 29:1383, 1969.PubMedCrossRefGoogle Scholar
  2. 2.
    Lloyd HM, Meares JD, Jacobi J: Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature (Lond) 255:497, 1975.CrossRefGoogle Scholar
  3. 3.
    Phelps C, Bartke A: Effect of chronic hyperprolactinemia on tuberoinfundibular dopaminergic neurons: Histofluorescence in male rats. In MacLeod RM, Thorner MO, Scapagnini U (eds): Prolactin. Basic and Clinical Correlates. Liviana, Padova, 1985, p. 615.Google Scholar
  4. 4.
    Franks S: Regulation of prolactin secretion by oestrogens: Physiological and pathological significance. Clin Sci 65:457, 1983.PubMedGoogle Scholar
  5. 5.
    Davis JRE, Selby C, Jeffcoate WJ: Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol (Oxf) 20:427, 1984.CrossRefGoogle Scholar
  6. 6.
    Weiner RI, Elias KA, Monnet F: The role of vascular changes in the etiology of prolactin secreting anterior pituitary tumors. In MacLeod RM, Thorner MO, Scapagnini U (eds): Prolactin: Basic and Clinical Correlates. Livana, Padova, 1985, p. 641.Google Scholar
  7. 7.
    Kovacs K, Korvath E, Cornblum B, et al: Pituitary chromophobe adenomas consisting of prolactin cells: A histologic, immunocytological and electron microscopic study. Virchows Arch [A] 366:113, 1975.CrossRefGoogle Scholar
  8. 8.
    Kovacs K: Morphology of prolactin producing adenomas. Clin Endocrinol (Oxf) 6:71s, 1977.CrossRefGoogle Scholar
  9. 9.
    Forbes AP, Henneman PH, Griswold GC, et al: Syndrome characterized by galactorrhea, amenorrhea and low urinary FSH: Comparison with acromegaly and normal lactation. J Clin Endocrinol Metab 14:265, 1954.PubMedCrossRefGoogle Scholar
  10. 10.
    Frommel R: Uber puerpale Atrophie des Uterus. Z Geburtsh Gynakol 7:305, 1882.Google Scholar
  11. 11.
    Franks S, Murray MAF, Jequier AM, et al: Incidence and significance of hyperprolactinemia in women with amenorrhea. Clin Endocrinol (Oxf) 4:597, 1975.CrossRefGoogle Scholar
  12. 12.
    Jacobs HW, Hull MGR, Murray MAF, et al: Therapy-oriented diagnosis of secondary amenorrhea. Horm Res 6:268, 1975.PubMedCrossRefGoogle Scholar
  13. 13.
    Frantz AG, Kleinberg DL, Noel GL: Studies on prolactin in man. Recent Prog Horm Res 28:527, 1972.PubMedGoogle Scholar
  14. 14.
    Franks S, Nabarro JDN, Jacobs HS: Prevalence and presentation of hyperprolactinemia in patients with “functionless” pituitary tumors. Lancet 1:778, 1977.PubMedCrossRefGoogle Scholar
  15. 15.
    Haesslein HC, Lamb EJ: Pituitary tumors in patients with secondary amenorrhea. Am J Obstet Gynecol 125:759, 1956.Google Scholar
  16. 16.
    Biller BJ, Boyd AE III, Moltich M, et al: Clinical features of pituitary tumors: Galactorrheasyndromes. In Post KD, Jackson IMD, Reichlin S (eds): Pituitary Adenoma Update. Plenum, New York, 1981, p. 65.Google Scholar
  17. 17.
    Besser GM, Wass JAH, Grossman A, et al: Clinical and therapeutic aspects of hyperprolactinemia. In MacLeod RM, Thorner MO, Scapagnini U (eds): Prolactin. Basic and Clinical Correlates. Liviana, Padova, 1985, p. 833.Google Scholar
  18. 18.
    Quigley ME, Sheehan KL, Casper RF, et al: Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinaemic patients with pituitary microadenoma. J Clin Endocrinol Metab 50:427, 1980.PubMedCrossRefGoogle Scholar
  19. 19.
    Grossman A, Moult PJA, Mclntyre H, et al: Opiate mediation of amenorrhoea in hyperprolactinaemia and in weight-loss related amenorrhoea. Clin Endocrinol (Oxf) 17:379, 1982.CrossRefGoogle Scholar
  20. 20.
    Thorner MO, Besser GM: Bromocriptine treatment of hyperprolactinemic hypogonadism, Acta Endocrinol (Suppl 216) (Copenh) 88:131, 1978.Google Scholar
  21. 21.
    Thorner MO: Prolactin. In Besser GM (ed): Clinics in Endocrinology and Metabolism. Vol. 6. WB Saunders, Philadelphia, 1977, p. 201.Google Scholar
  22. 22.
    Jacobs HS, Franks S, Murray MAF, et al: Clinical and endocrine features of hyperprolactinemic amenorrhea. Clin Endocrinol (Oxf) 5:439, 1976.CrossRefGoogle Scholar
  23. 23.
    Molitch ME, Reichlin S: The amenorrhea, galactorrhea and hyperprolactinemia syndromes. In Stollerman GH (ed): Advances in Internal Medicine. Year Book Medical, Chicago, 1980, pp. 37–60.Google Scholar
  24. 24.
    Lavric MV: Breast secretion in nulligravid women. Am J Obstet Gynecol 112:1139, 1972.PubMedGoogle Scholar
  25. 25.
    Shevach AB, Spellacy WN: Galactorrhea and contraceptive practices. Obstet Gynecol 38:286, 1971.PubMedGoogle Scholar
  26. 26.
    Hardy J, Beauregard H, Robert F: Prolactin-secreting pituitary adenomas: Transsphenoidal microsurgical treatment. In Robyn C, Harter M (eds): Progress in Prolactin Physiology and Pathology. Elsevier, New York, 1978, p. 361.Google Scholar
  27. 27.
    Carter JN, Tyson JE, Tolis G, et al: Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 299:847, 1978.PubMedCrossRefGoogle Scholar
  28. 28.
    Ambrosi B, Rosella B, Travaglini P, et al: Study of the effect of bromocriptine on sexual impotence. Clin Endocrinol (Oxf) 7:417, 1977.CrossRefGoogle Scholar
  29. 29.
    Skrabanek P, McDonald D, deValera E, et al: Plasma prolactin in amenorrhea, infertility and other disorders: A retrospective study of 608 patients. Ir J Med Sci 149:236, 1980.PubMedCrossRefGoogle Scholar
  30. 30.
    Spark RF, White RA, Connolly PB: Impotence is not always psychogenic. JAMA 243:750, 1980.PubMedCrossRefGoogle Scholar
  31. 31.
    Segal S, Yaffee H, Laufer N, et al: Male hyperprolactinemia: Effects on fertility. Fertil Steril 32:556, 1979.PubMedGoogle Scholar
  32. 32.
    Boyd AE III, Hamilton D, Murray BG, et al: Medical management of prolactinomas. II. In Black PM, Zervas NT, Ridgway EC, et al (eds): Secretory Tumors of the Pituitary Gland. Progress in Endocrine Research and Therapy. Vol 1. Raven, New York, 1984, p. 65.Google Scholar
  33. 33.
    Thorner MO, Edwards CRW, Hanker JP, et al: Prolactin and gonadotropin interaction in the male. In Troen P, Nankin H (eds): The Testis in Normal and Infertile Men. Raven, New York, 1977, pp. 351–366.Google Scholar
  34. 34.
    Kleinberg DL, Noel GL, Frantz AG: Galactorrhea: 235 cases including 48 with pituitary tumors. N Engl J Med 296:589, 1977.PubMedCrossRefGoogle Scholar
  35. 35.
    Bassi F, Guisti G, Borsi L, et al: Plasma androgens in women with hyperprolactinemic amenorrhea. Clin Endocrinol (Oxf) 5:61, 1977.Google Scholar
  36. 36.
    Molitch ME, Reichlin S: Hypothalamic hyperprolactinemia: Neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. In MacLeod RM, Thorner MO, Scapagnini U (eds): Prolactin. Basic and Clinical Correlates. Liviana, Padova, 1985, p. 709.Google Scholar
  37. 37.
    Johnston DG, Haigh J, Prescott RWG, et al: Prolactin secretion and biological activity in females with galactorrhoea and normal circulating prolactin concentrations at rest. Clin Endocrinol (Oxf) 22:661, 1985.CrossRefGoogle Scholar
  38. 38.
    VanWyk JJ, Grumbach MM: Syndrome of precocious menstuation and galactorrhea in juvenile hypothyroidism. An example of hormonal overlap in pituitary feedback. J Pediatr 57:416, 1960.CrossRefGoogle Scholar
  39. 39.
    Honbo KS, Van herle AJ, Kellett KA, et al: Serum prolactin levels in untreated primary hypothyroidism. Am J Med 64:782, 1978.PubMedCrossRefGoogle Scholar
  40. 40.
    Contreras P, Generini G, Michelsen H, et al: Hyperprolactinemia and galactorrhea: Spontaneous versus iatrogenic hypothyroidism. J Clin Endocrinol Metab 53:1036, 1981.PubMedCrossRefGoogle Scholar
  41. 41.
    Kapcala LP: Galactorrhea and thyrotoxicosis. Arch Intern Med 144:2349, 1984.PubMedCrossRefGoogle Scholar
  42. 42.
    Tourniaire J, Trouillas J, Chalendar D, et al: Somatotropic adenoma manifested by galactorrhea without acromegaly. J Clin Endocrinol Metab 61:451, 1985.PubMedCrossRefGoogle Scholar
  43. 43.
    Taylor S: High resolution computed tomography of the sella. Radiol Clin North Am 20:207, 1982.PubMedGoogle Scholar
  44. 44.
    Wolpert SM: The radiology of pituitary adenomas. Semin Roentgenol 19:53, 1984.PubMedCrossRefGoogle Scholar
  45. 45.
    Gardeur D, Naidich TP, Metzger J: CT analysis of intrasellar pituitary adenomas with emphasis on patterns of contrast enhancement. Neuroradiology 20:241, 1981.PubMedCrossRefGoogle Scholar
  46. 46.
    Hsu T-H, Shapiro JR, Tyson JE, et al: Hyperprolactinemia associated with empty sella syndrome. JAMA 235:2002, 1976.PubMedCrossRefGoogle Scholar
  47. 47.
    Badawy SZA, Nusbaum ML, Omar M: Hypothalamic-pituitary evaluation in patients with galactorrhea-amenorrhea and hyperprolactinemia. Obstet Gynecol 55:1, 1980.PubMedGoogle Scholar
  48. 48.
    Gharib H, Frey HM, Laws ER Jr, et al: Coexistent primary empty sella syndrome and hyperprolactinemia: Report of 11 cases. Arch Intern Med 143:1383, 1983.PubMedCrossRefGoogle Scholar
  49. 49.
    Haney AF, Kramer RS, Wiebe RH, et al: Hypothalamic-pituitary function and radiographic evaluation of women with hyperprolactinemia and an empty sella turcica. Am J Obstet Gynecol 134:917, 1979.PubMedGoogle Scholar
  50. 50.
    Futterweit W: Galactorrhea, amenorrhea, hyperprolactinemia and pseudotumor cerebri in a patient with primary empty sella syndrome: Case report with review of the literature. Mt Sinai J Med 49:514, 1982.PubMedGoogle Scholar
  51. 51.
    Dominque JN, Wing SD, Wilson CB: Coexisting pituitary adenomas and partially empty sellas. J Neurosurg 48:23 ,1978.CrossRefGoogle Scholar
  52. 52.
    Swanson JA, Sherman BM, Van Gilder JC, et al: Coexistent empty sella and prolactinsecreting microadenoma. Obstet Gynecol 53:258, 1979.PubMedGoogle Scholar
  53. 53.
    Archer DF, Maroon JC, DuBois PJ: Galactorrhea, amenorrhea, hyperprolactinemia, and an empty sella. Obstet Gynecol 52(Suppl):23, 1978.Google Scholar
  54. 54.
    Jones JR, DeHempel PAC, Kemmann E, et al: Galactorrhea and amenorrhea in a patient with an empty sella. Obstet Gynecol 49:S9, 1977.Google Scholar
  55. 55.
    Gomez F, Reyes F, Faiman C: Nonpuerperal galactorrhea and hyperprolactinemia. Am J Med 62:648, 1977.PubMedCrossRefGoogle Scholar
  56. 56.
    Archer DF, Spring JW, Nankin HR, et al: Pituitary and gonadotrophin response in women with idiopathic hyperprolactinemia. Fertil Steril 27:1158, 1976.PubMedGoogle Scholar
  57. 57.
    Aono T, Myake T, Shiroji T, et al: Impaired LH release following exogenous estrogen administration in patients with amenorrhea-galactorrhea syndrome. J Clin Endocrinol Metab 42:696, 1976.PubMedCrossRefGoogle Scholar
  58. 58.
    Mortimer CH, Besser GH, McNeilly AD, et al: Luteinizing hormone and follicle stimulating hormone releasing hormone test in patients with hypothalamic pituitary gonadal dysfunction. Br Med J 4:73, 1973.PubMedCrossRefGoogle Scholar
  59. 59.
    Wiebe RH, Hammond CB, Borchert LG: Diagnosis of prolactin-secreting pituitary microadenoma. Am J Obstet Gynecol 126:993, 1976.PubMedGoogle Scholar
  60. 60.
    Lackelin GCL, Abu-Fadil S, Yen SSC: Functional delineation of hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 44:1163, 1977.CrossRefGoogle Scholar
  61. 61.
    Van Campenhout J, Papas S, Blanchet P: Pituitary responses to synthetic luteinizing hormone-releasing hormone in thirty-four cases of amenorrhea or oligo-amenorrhea associated with galactorrhea. Am] Obstet Gynecol 127:723, 1977.Google Scholar
  62. 62.
    Zarate Z, Jacobs LS, Canales ES: Functional evaluation of pituitary reserve in patients with the amenorrhea-galactorrhea syndrome utilizing luteinizing releasing hormone (LH-RH), L-dopa and chlorpromazine. J Clin Endocrinol Metab 37:855, 1973.PubMedCrossRefGoogle Scholar
  63. 63.
    Chang RJ, Keye WR, Young JR, et al: Detection, evaluation and treatment of pituitary microadenomas in patients with galactorrhea and amenorrhea. Am J Obstet Gynecol 128:357, 1977.Google Scholar
  64. 64.
    Lamberts SWJ, Birkenhäger JC, Kwa HG: Basal and TRH-stimulated prolactin in patients with pituitary tumours. Clin Endocrinol (Oxf) 5:709, 1976.CrossRefGoogle Scholar
  65. 65.
    Barbarino A, de Marinis L, Menini E, et al: Prolactin-secreting pituitary adenomas: Prolactin dynamics before and after transsphenoidal surgery. Acta Endocrinol (Kbh) 91:397, 1979.Google Scholar
  66. 66.
    Cowden EA, Ratcliffe JG, Thomson JA, et al: Tests of prolactin secretion in diagnosis of prolactinomas. Lancet 1:1155, 1979.PubMedCrossRefGoogle Scholar
  67. 67.
    Healy DL, Pepperell RJ, Stockdale J, et al: Pituitary autonomy in hyperprolactinemic secondary amenorrhea: Results of hypothalamic-pituitary testing. J Clin Endocrinol Metab 44:809, 1977.PubMedCrossRefGoogle Scholar
  68. 68.
    Jeske W: The effect of metoclopramide, TRH and L-dopa on prolactin secretion in pituitary adenoma and in “functional” galactorrheoea syndrome. Acta Endocrinol (Kbh) 91:385, 1979.Google Scholar
  69. 69.
    Schlechte JA, Sherman BM: Abnormal regulation of prolactin secretion after successful surgery for prolactin-secreting pituitary tumours. Clin Endocrinol (Oxf) 15:165, 1981.CrossRefGoogle Scholar
  70. 70.
    Frantz AG: Endocrine diagnosis of prolactin-secreting pituitary tumors. In Black PM, Zervas NT, Ridgway EC, et al. (eds): Secretory Tumors of the Pituitary Gland. Progress in Endocrine Research and Therapy. Vol 1. Raven, New York, 1984, p. 45.Google Scholar
  71. 71.
    Fine SA, Frohman LA: Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin secreting pituitary tumors. J Clin Invest 61:973, 1978.PubMedCrossRefGoogle Scholar
  72. 72.
    Crosignani PG, Ferrari C, Malinverni A, et al: Effect of central nervous system dopaminergic activation on prolactin secretion in man: Evidence for a common central defect in hyperprolactinemic patients with and without radiological signs of pituitary tumors. J Clin Endocrinol Metab 51:1068, 1980.PubMedCrossRefGoogle Scholar
  73. 73.
    Genazzani ZR, De Leo V, Murru S, et al: Dynamic tests of prolactin secretion in hyperprolactinemic states: Carbidopa-L-dopa and indirectly acting dopamine agonists. J Clin Endocrinol Metab 54:429, 1982.PubMedCrossRefGoogle Scholar
  74. 74.
    Moriondo P, Travaglini P, Nisim M, et al: Evaluation of two inhibitory tests (nomifensine and L-dopa + carbidopa) for the diagnosis of hyperprolactinaemic states. Clin Endicrinol (Oxf) 13:525, 1980.CrossRefGoogle Scholar
  75. 75.
    Muller EE, Genazzani AR, Murru S: Nomifensine: diagnostic test in hyperprolactinemic states. J Clin Endocrinol Metab 47:1352, 1978.PubMedCrossRefGoogle Scholar
  76. 76.
    Ferrari C, Crosignani PG, Caldara MC, et al: Failure of nomifensine administration to discriminate between tumorous and nontumorous hyperprolactinemia. J Clin Endocrinol Metab 50:23, 1979.CrossRefGoogle Scholar
  77. 77.
    Kamoi K, Tchuchida I, Sato H, et al: Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors. J Clin Endocrinol Metab 53:1285, 1981.PubMedCrossRefGoogle Scholar
  78. 78.
    Camanni F, Genazzani AR, Massara F, et al: Prolactin responsiveness to nomifensine in patients with hyperprolactinemia of tumorous or uncertain etiology. J Clin Endocrinol Metab 51:650, 1980.PubMedCrossRefGoogle Scholar
  79. 79.
    Dallabonzana D, Spelta B, Botalla L, et al: Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia. J Clin Endocrinol Metab 54:1125, 1982.PubMedCrossRefGoogle Scholar
  80. 80.
    Martin TL, Kim M, Malarkey WB: The natural history of idiopathic hyperprolactinemia. / Clin Endocrinol Metab 60:855, 1985.CrossRefGoogle Scholar
  81. 81.
    Malarkey WB, Martin TL, Kim M: Patients with idiopathic hyperprolactinemia infrequently develop pituitary tumors. In MacLeod RM, Throner MO, Scapagnini U (eds): Prolactin. Basic and Clinical Correlates. Liviana, Padova, 1985, p. 705.Google Scholar
  82. 82.
    Jackson RD, Wortsman J, Malarkey WB: Characterization of a large molecular weight prolactin in women with idiopathic hyperprolactinemia and normal menses. J Clin Endocrinol Metab 61:258, 1985.PubMedCrossRefGoogle Scholar
  83. 83.
    Post KD, Kasdon DL: Sellar and parasellar lesions mimicking adenoma. In Post KD, Jackson I, Reichlin S, et al. (eds): The Pituitary Adenoma. Plenum, New York, 1980, p. 159.Google Scholar
  84. 84.
    Stuart CA, Neelon FA, Lebovitz HE: Hypothalamic insufficiency: The cause of hypopituitarism in sarcoidosis. Ann Intern Med 88:589, 1978.PubMedGoogle Scholar
  85. 85.
    Vesely DL, Maldonodo A, Levey GS: Partial hypopituitarism and possible hypothalamic involvement in sarcoidosis: Report of a case and review of the literature. Am J Med 62:425, 1977.PubMedCrossRefGoogle Scholar
  86. 86.
    Asa SL, Bilbao JM, Kovacs K, et al: Lymphocytic hypophysitis of pregnancy resulting in hypopituitarism: A distinct clinicopathologic entity. Ann Intern Med 95:166, 1981.PubMedGoogle Scholar
  87. 87.
    Mayfield RK, Levine JH, Gordon L, et al: Lymphoid adenohypophysitis presenting as a pituitary tumor. Am J Med 69:619, 1980.PubMedGoogle Scholar
  88. 88.
    Rickards AG, Harvey PW: Giant cell granuloma and the other pituitary granulomata. Q J Med 23:425, 1954.PubMedGoogle Scholar
  89. 89.
    Hoick S, Laursen H: Prolactinoma coexistent with granulomatous hypophysitis. Acta Neuropathol (Berl) 61:253, 1983.CrossRefGoogle Scholar
  90. 90.
    Abrams HL, Spiro R, Goldstein N: Metastases in carcinoma: Analysis of 1000 autopsied cases. Cancer 3:74, 1950.PubMedCrossRefGoogle Scholar
  91. 91.
    Hagerstrand I, Schonebeck J: Metastases to the pituitary gland. Acta Pathol Microbiol Scand 75:64, 1969.PubMedGoogle Scholar
  92. 92.
    Kovacs K: Metastatic cancer of the pituitary gland. Oncology 27:533, 1973.PubMedCrossRefGoogle Scholar
  93. 93.
    Teears RJ, Silverman EM: Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland. Cancer 36:216, 1975.PubMedCrossRefGoogle Scholar
  94. 94.
    Stacpoole PW, Kandell TW, Fisher WR: Primary empty sella, hyperprolactinemia and isolated ACTH deficiency after postpartum hemorrhage. Am J Med 74:905, 1983.PubMedCrossRefGoogle Scholar
  95. 95.
    Merker E, Futterweit W: Postpartum amenorrhea, diabetes insipidus and galactorrhea. Am J Med 56:554, 1974.PubMedCrossRefGoogle Scholar
  96. 96.
    Dadey SL, Hurxthal LM: Abnormal lactation: Report of a case with amenorrhea and diabetes insipidus. Lahey Clin Bull 10:166, 1957.PubMedGoogle Scholar
  97. 97.
    Boyd AE III, Reichlin S, Turksoy RN: Galactorrhea-amenorrhea syndrome: Diagnosis and therapy. Ann Intern Med 87:165, 1977.PubMedGoogle Scholar
  98. 98.
    Maas JM: Amenorrhea-galactorrhea syndrome: Before, during and after pregnancy. Fertil Steril 18:857, 1967.PubMedGoogle Scholar
  99. 99.
    Koppelman MCS, Jaffe MJ, Rieth KG, et al: Hyperprolactinemia, amenorrhea, and galactorrhea: A retrospective assessment of twenty-five cases. Ann Intern Med 100:115, 1984.PubMedGoogle Scholar
  100. 100.
    Weiss MH, Teal J, Gott P, et al: Natural history of microprolactinomas: Six-year follow-up. Neurosurgery 12:180, 1983.PubMedCrossRefGoogle Scholar
  101. 101.
    March CM, Kletzky OA, Davajan V, et al: Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139:835, 1981.PubMedGoogle Scholar
  102. 102.
    Besser GM, Parke L, Edwards CRW, et al: Galactorrhoea: Successful treatment with reduction of plasma prolactin levels by bromergocryptine. Br Med J 3:669, 1972.PubMedCrossRefGoogle Scholar
  103. 103.
    Yuen BH: Bromocriptine, pituitary tumours and pregnancy. Lancet 2:1314, 1978.PubMedCrossRefGoogle Scholar
  104. 104.
    Thorner MO, Evans WS, MacLeod RM, et al: Hyperprolactinemia: Current concepts of management including medical therapy with bromocriptine. Adv Biochem Psychopharmacol 23:165, 1980.PubMedGoogle Scholar
  105. 105.
    Parkes D: Drug therapy: Bromocryptine. N Engl] Med 301:873, 1979.CrossRefGoogle Scholar
  106. 106.
    Nagulesparen M, Ang V, Jenkins JS: Bromocriptine treatment of males with pituitary tumors, hyperprolactinaemia, and hypogonadism. Clin Endocrinol (Oxf) 9:73, 1978.CrossRefGoogle Scholar
  107. 107.
    Mroueh AM, Siler-Khodr TM: Bromocriptine therapy in cases of amenorrhea-galactorrhea. Am J Obstet Gynecol 127:291, 1977.PubMedGoogle Scholar
  108. 108.
    Fluckiger E: Pharmacology of prolactin secretion. In Falbusch R, et al (eds): Treatment of Pituitary Adenomas. Little, Brown, Boston, 1978, p. 351.Google Scholar
  109. 109.
    Aronoff SL, Daughaday WH, Laws ER Jr: Bromocriptine treatment of prolactinomas. (Letter.) N Engl J Med 300:1391, 1979.PubMedCrossRefGoogle Scholar
  110. 110.
    Besser GM, Mouk PJA: Prolactinomas and their management. In Jacobs HS (ed): Advances in Gynecological Endocrinology. 6th ed. London Royal College of Obstetricians and Gynecologists, London, 1978, p. 234.Google Scholar
  111. 111.
    Barrow DL, Tindall GT, Kovacs K, et al: Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg 60:1, 1984.PubMedCrossRefGoogle Scholar
  112. 112.
    Bergh T, Nillius SJ, Wide L: Bromocriptine treatment of seven women with primary amenorrhea and prolactin-secreting pituitary tumors. Clin Endocrinol (Oxf) 10:145, 1979.CrossRefGoogle Scholar
  113. 113.
    Vance ML, Evans WS, Thorner MO: Drugs five years later: Bromocriptine. Ann Intern Med 100:78, 1983.Google Scholar
  114. 114.
    Velentzas C, Carras D, Vassilouthis J: Regression of pituitary prolactinoma with bromocriptine administration. JAMA 245:1149, 1981.PubMedCrossRefGoogle Scholar
  115. 115.
    Tindall GT, Kovacs K, Horvath E, et al: Human prolactin-producing adenomas and bromocriptine: A histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178, 1982.PubMedCrossRefGoogle Scholar
  116. 116.
    Thorner MO, Schran HF, Evans WS, et al: A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after acute and chronic administraiton of bromocriptine. J Clin Endocrinol Metab 50:1026, 1980.PubMedCrossRefGoogle Scholar
  117. 117.
    Thorner MO, Edwards CRW, Charlesworth M, et al: Pregnancy in patients presenting with hyperprolactinaemia. Br Med J 2:771, 1979.PubMedCrossRefGoogle Scholar
  118. 118.
    Thorner MO, Besser GM: Bromocriptine treatment of hyperprolactinaemic hypogonadism. Acta Endocrinol (Copenh) [Suppl 216] 88:131, 1978.Google Scholar
  119. 119.
    Wass JAH, Moult PJA, Thorner MO, et al: Reduction of pituitary tumor size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 2:66, 1979.PubMedCrossRefGoogle Scholar
  120. 120.
    Wass JAH, Williams J, Charlesworth M, et al: Bromocriptine in management of large pituitary tumors. Br Med J 284:1908, 1982.CrossRefGoogle Scholar
  121. 121.
    Clayton RN, Webb J, Heath DA, et al: Dramatic and rapid shrinkage of a massive invasive prolactinoma with bromocriptine: A case report. Clin Endocrinol (Oxf) 22:573, 1985.CrossRefGoogle Scholar
  122. 122.
    Chiodini P, Liuzzi A, Cozzi R, et al: Size reduction of macroprolactinomas by bromocriptine or lisguride treatment. J Clin Endocrinol Metab 53:737, 1981.PubMedCrossRefGoogle Scholar
  123. 123.
    George SR, Burrow GN, Zinman B, et al: Regression of pituitary tumors, a possible effect of bromergocryptine. Am J Med 66:697, 1979.PubMedCrossRefGoogle Scholar
  124. 124.
    Grisoli F, Vincentelli F, Jaquet P, et al: Prolactin secreting adenomas in 22 men. Surg Neurol 13:241, 1980.PubMedGoogle Scholar
  125. 125.
    McGregor AM, Scanlon MF, Hall K, et al: Reduction in size of a pituitary tumor by bromocriptine therapy. N Engl J Med 300:291, 1979.PubMedCrossRefGoogle Scholar
  126. 126.
    Vaidya RA, Aloorkar SD, Rege NR: Normalization of visual fields following bromocriptine treatment in hyperprolactinemic patients with visual field constriction. Fertil Steril 29:632, 1978.PubMedGoogle Scholar
  127. 127.
    Thorner MO, Martin WH, Rogol AD, et al: Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 51:438, 1980.PubMedCrossRefGoogle Scholar
  128. 128.
    Thorner MO, Perryman RL, Rogol AD, et al: Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 153:480, 1981.CrossRefGoogle Scholar
  129. 129.
    Wollesen FO, Andersen T, Karle A: Size reduction of extrasellar pituitary tumors during bromcriptine treatment: Quantitation of effect on different types of tumors. Ann Intern Med 96:281, 1982.PubMedGoogle Scholar
  130. 130.
    Nillius SJ, Bergh T, Lundberg PO, et al: Regression of a prolactin-secreting pituitary tumor during long-term treatment with bromocriptine. Fertil Steril 30:710, 1978.PubMedGoogle Scholar
  131. 131.
    Landolt AM, Wutrich R, Fellmann H: Regression of pituitary prolactinoma after treatment with bromocriptine. Lancet 1:1082, 1979.PubMedCrossRefGoogle Scholar
  132. 132.
    Corenblum B, Webster BR, Mortimer CB, et al: Possible antitumor effects of 2-bromoergocryptine (CB-154 Sandoz) in 2 patients with large prolactin-secreting pituitary adenomas. Clin Res 23:614A, 1975.Google Scholar
  133. 133.
    Nabarro JDN: Pituitary prolactinomas. Clin Endocrinol (Oxf) 17:129, 1982.CrossRefGoogle Scholar
  134. 134.
    MacLeod RM, Lehmeyer JE: Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94:1077, 1974.PubMedCrossRefGoogle Scholar
  135. 135.
    Mashiter K, Adams E, Bear M, et al: Bromocriptine inhibits prolactin and growth-hormone release by human pituitary tumours in culture. Lancet 2:197, 1977.PubMedCrossRefGoogle Scholar
  136. 136.
    Sobrinho LG, Nunes MC, Calhaz-Jorge C, et al: Effect of treatment with bromocriptine on the size and activity of prolactin-producing pituitary tumors. Acta Endocrinol (Copenh) 96:24, 1981.Google Scholar
  137. 137.
    Eversmann T, Fahlbusch R, Rjosk HK, et al: Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Acta Endocrinol (Copenh) 92:413, 1979.Google Scholar
  138. 138.
    Grossman A, Bouloux P-MG, Loneragan R, et al: Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia. Clin Endocrinol (Oxf) 22:611, 1985.CrossRefGoogle Scholar
  139. 139.
    Kleinberg DL, Lieberman A, Todd J, et al: Pergolide mesylate: A potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson’s disease. J Clin Endocrinol Metab 51:152, 1980.PubMedCrossRefGoogle Scholar
  140. 140.
    Franks S, Horrocks PM, Lynch SS, et al: Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia. Br Med J 286:1177, 1983.CrossRefGoogle Scholar
  141. 141.
    Kleinberg DL, Boyd AE III, Wardlaw S, et al: Treatment of prolactin and growth hormone secreting pituitary tumors with pergolide. N Engl J Med 309:704, 1983.PubMedCrossRefGoogle Scholar
  142. 142.
    Hardy J, Beauregard H, Robert F: Prolactin-secreting adenomas: Transsphenoidal microsurgical treatment. In Robyn C, et al (eds): Progress in Prolactin Physiology and Pathology. Elsevier/North-Holland, New York, 1978, p. 361.Google Scholar
  143. 143.
    Hardy J: Transsphenoidal surgery of hypersecreting pituitary tumors. In Kohler PO, Ross GT (eds): Diagnosis and Treatment of Pituitary Tumors. Excerpta Medica, Amsterdam, 1973, p. 179.Google Scholar
  144. 144.
    Hardy J: Transsphenoidal microsurgical removal of pituitary microadenoma. In Krayenbühl H, Maspes PE, Sweet WH (eds): Progress in Neurological Surgery. S. Karger, Basel, 1975, p. 200.Google Scholar
  145. 145.
    Hardy J, Vezina JL: Transsphenoidal neurosurgery of intracranial neoplasm. In Thompson RA, Greene JR (eds): Advances in Neurology. Raven Press, New York, 1976, p. 261.Google Scholar
  146. 146.
    Hardy J: Microsurgical exploration of a normal sella turcia for a microadenoma. In Derome JP, Jedynak CP, Peillon F (eds): Pituitary Adenomas: Biology, Physiopathology and Treatment. Asclepios, France, 1980, p. 195.Google Scholar
  147. 147.
    Hardy J (ed): Prolactinoma. Neurochirurgie 27(Suppl 1), 1981.Google Scholar
  148. 148.
    Chang RJ, Keye WR Jr, Young JR: Detection, evaluation, and treatment of pituitary microadenomas in patients with galactorrhea and amenorrhea. Am J Obstet Gynecol 128:356, 1977.PubMedGoogle Scholar
  149. 149.
    Jacques P, Grisoli F, Guibout M, et al: Prolactin secreting tumors: Endocrine status before and after surgery in 33 women. J Clin Endocrinol Metab 46:459, 1978.CrossRefGoogle Scholar
  150. 150.
    Tucker H St G, Grubb SR, Wigand JP, et al: Galactorrhea-amenorrhea syndrome: Follow-up of forty five patients after pituitary tumor removal. Ann Intern Med 94:302, 1981.PubMedGoogle Scholar
  151. 151.
    Post KD, Biller BJ, Adelman LS, et al: Selective transsphenoidal adenomectomy in women with galactorrhea-amenorrhea. JAMA 242:158, 1979.PubMedCrossRefGoogle Scholar
  152. 152.
    Tindall GT, McLanahan S, Christy JH: Transsphenoidal microsurgery for pituitary tumors associated with hyperprolactinemia. J Neurosurg 48:849, 1978.PubMedCrossRefGoogle Scholar
  153. 153.
    Wilson Ch.B, Dempsey SC: Transsphenoidal microsurgical removal of 250 pituitary adenomas. J Neurosurg 48:13, 1978.PubMedCrossRefGoogle Scholar
  154. 154.
    Domingue JN, Richmond IL, Wilson CB: Results of surgery in 114 patients with prolactinsecreting pituitary adenomas. Am J Obstet Gynecol 137:102, 1980.PubMedGoogle Scholar
  155. 155.
    Faria MA Jr, Tindall GT: Transsphenoidal microsurgery for prolactinomas. In Givens Jr (ed): Hormone Secreting Pituitary Tumors. Year Book, Chicago, 1982, p. 275.Google Scholar
  156. 156.
    Hardy J: Transsphenoidal microsurgery of prolactinomas. In Black P McL, et al. (eds): Progress in Endocrine Research and Therapy. Vol. 1. Raven Press, New York, 1984, p. 73.Google Scholar
  157. 157.
    Serri O, Rasio E, Beauregard H, et al: Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl] Med 309:280, 1983.CrossRefGoogle Scholar
  158. 158.
    Rodman EF, Molitch ME, Post KD, et al: Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma. JAMA 252:921, 1984.PubMedCrossRefGoogle Scholar
  159. 159.
    Antunes JL, Housepian EM, Frantz AG, et al: Prolactin-secreting pituitary tumors. Ann Neurol 2:148, 1977.CrossRefGoogle Scholar
  160. 160.
    Sheline GE, Grossman A, Jones AE, et al: Radiation therapy for prolactinomas. In Black P McL, et al. (eds): Secretory Tumors of the Pituitary Gland. Progress in Endocrine Research and Therapy. Vol. 1. Raven Press, New York, 1984, p. 93.Google Scholar
  161. 161.
    Grossman A, Cohen BL, Charlesworth M, et al: The circulating prolactin response to radiotherapy in patients with prolactinoma. Br Med J 288:1105, 1984.CrossRefGoogle Scholar
  162. 162.
    Grossman A, Besser GM: Prolactinomas. Br Med J 290:182, 1985.CrossRefGoogle Scholar
  163. 163.
    Robinson AG, Nelson PB: Prolactinomas in women: Current therapies. Ann Intern Med 99:115, 1983.PubMedGoogle Scholar
  164. 164.
    Turkalj I, Braun P, Krupp P: Surveillance of bromocriptine in pregnancy. JAMA 247:1589, 1982.PubMedCrossRefGoogle Scholar
  165. 165.
    Lamberts SWJ, Klijn JGM, deLange SA, et al: The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with radiologically evident pituitary tumors. Fertil Steril 31:614, 1979.PubMedGoogle Scholar
  166. 166.
    Griffith RW, Turkalj I, Braun P: Pituitary tumors during pregnancy in mothers treated with bromocriptine. Br J Clin Pharmacol 1:393, 1979.Google Scholar
  167. 167.
    Gemzell C, Wang CF: Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 31:363, 1979.PubMedGoogle Scholar
  168. 168.
    Molitch ME, Elton RL, Blackwell RE, et al: Bromocriptine as primary therapy for prolactinsecreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 60:698, 1985.PubMedCrossRefGoogle Scholar
  169. 169.
    Warfield A, Finkel DM, Schatz NJ, et al: Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. Ann Intern Med 101:783, 1984.PubMedGoogle Scholar
  170. 170.
    Johnston DG, Prescott RWG, Kendall-Taylor P, et al: Hyperprolactinemia. Long-term effects of bromocriptine. Am J Med 75:868, 1983.PubMedCrossRefGoogle Scholar
  171. 171.
    Spark RF, Baker R, Bienfang DC, et al: Bromocriptine reduces pituitary tumor size and hypersecretion. JAMA 247:311, 1982.PubMedCrossRefGoogle Scholar
  172. 172.
    Molitch ME: Pregnancy and the hyperprolactinemic woman. N Engl J Med 312:1364, 1985.PubMedCrossRefGoogle Scholar
  173. 173.
    Barbieri RL, Ryan KJ: Bromocriptine: Endocrine pharmacology and therapeutic applications. Fertil Steril 39:727, 1983.PubMedGoogle Scholar
  174. 174.
    Adelman LS: The Pathology of Pituitary Adenomas. In Post KD, Jackson IM, Reichlin S (eds): The Pituitary Adenoma ,Plenum Press, New York, 1980, pp. 47–62.Google Scholar
  175. 175.
    Wolpert SM: The Radiology of Pituitary Adenomas. In Post KD, Jackson IM, Reichlin S (eds): The Pituitary Adenoma ,Plenum Press, New York, 1980, pp. 297–320.Google Scholar
  176. 176.
    Post KD, Kasdon DL: Sellar and Parasellar Lesions Mimicking Adenoma. In Post KD, Jackson IM, Reichlin S (eds): The Pituitary Adenoma ,Plenum Press, New York, 1980, pp. 159–216.Google Scholar

Copyright information

© Plenum Publishing Corporation 1987

Authors and Affiliations

  • C. R. Kannan
    • 1
    • 2
  1. 1.Division of Endocrinology and Metabolism Department of MedicineCook County HospitalChicagoUSA
  2. 2.University of Illinois at ChicagoChicagoUSA

Personalised recommendations